Xanthone Derivatives Eliminate HBV cccDNA
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic hepatitis B, such as interferons and nucleos(t)ide analogues, fail to effectively eliminate or permanently silence covalently closed circular DNA (cccDNA), the source of chronic hepatitis B infection, leading to ongoing viral replication and liver damage.
Innovation Solution
Development of novel xanthone derivatives that act as cccDNA inhibitors, capable of inhibiting the persistence of cccDNA in hepatocytes, thereby addressing the limitations of existing therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments (interferons and nucleos(t)ide analogues) are used to treat chronic hepatitis B, then viral load is reduced and liver function improves, but cccDNA cannot be eliminated or permanently silenced
Solution Approach 1:
The patent extracts the specific function of eliminating cccDNA from the general antiviral treatment approach. The compounds of formula I are designed to specifically target and eliminate cccDNA from hepatocyte nuclei, separating this function from the viral replication inhibition performed by existing NAs and IFNs.
Solution Approach 2:
The patent changes the therapeutic parameter from viral replication inhibition to cccDNA elimination. The compounds of formula I achieve this by altering the fundamental approach - instead of blocking viral processes, they directly eliminate the persistent cccDNA reservoir through a novel mechanism of action.
2Productivity
If nucleos(t)ide analogues are used to inhibit HBV reverse transcriptase, then viral replication is suppressed, but drug resistance develops and treatment duration becomes infinite
Solution Approach 1:
The patent extracts the elimination function from the replication inhibition mechanism. By directly eliminating cccDNA rather than suppressing replication, the compounds avoid the resistance development associated with targeting viral enzymes like reverse transcriptase.
Solution Approach 2:
Instead of preventing viral replication through enzyme inhibition (the conventional approach), the patent inverts the strategy by directly eliminating the persistent cccDNA template. This reversal of the therapeutic approach avoids the resistance issues inherent in enzyme-targeting therapies.
3Reliability
If interferon treatment is administered to achieve sustained virological response, then HBsAg loss occurs in small percentage of patients, but severe side effects occur and treatment response remains limited
Solution Approach 1:
The patent extracts the cccDNA elimination function from the complex immunomodulatory mechanism of interferon. The compounds of formula I directly eliminate cccDNA through a simplified mechanism, separating this beneficial effect from the severe side effects associated with systemic interferon therapy.
Solution Approach 2:
The patent creates a small molecule compound version of the cccDNA elimination effect achieved by interferon. The compounds of formula I replicate the desired outcome (cccDNA elimination and HBsAg loss) without requiring the complex immunomodulatory pathway of interferon, thereby avoiding its side effects.
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present invention provides novel compounds having the general formula (I) wherein R1 to R6, X, Y, A1 and A2 are as described herein, compositions including the compounds and methods of using the compounds.